Transaction DateRecipientSharesTypePriceValue
13th November 2020Joel Lewis6,061Grant/award etc.$2.75$16,667.75
30th October 2020Joel Lewis6,562Grant/award etc.$2.54$16,667.48
15th October 2020Joel Lewis5,807Grant/award etc.$2.87$16,666.09
13th October 2020Fund, L.P. 10 X10,000Open or private sale$2.97$29,700.00
30th September 2020Joel Lewis6,242Grant/award etc.$2.67$16,666.14
29th September 2020Gilbert S Omenn20,000Open or private purchase$5.00$100,000.00
15th September 2020Joel Lewis5,171Grant/award etc.$2.93$15,151.03
4th September 2020Kevin D Freeman5,000Open or private purchase$2.57$12,848.00
4th September 2020Richard E Uihlein10,000Open or private purchase$2.55$25,500.00
19th March 2020Kevin D Freeman6,000Open or private purchase$1.64$9,844.20
Galectin Therapeutics
Galectin Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Galectin Therapeutics, Inc. engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Ticker: GALT
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1133416
Employees: 7
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $41 M (0%)
Assets, Current: $41 M (-14%)
Other Assets, Noncurrent: $197 Th (-23%)
Assets: $41 M (-14%)
Accounts Payable, Current: $206 Th (-87%)
Accrued Liabilities, Current: $4 M (266%)
Liabilities, Current: $4 M (51%)
Other Liabilities, Noncurrent: $31 Th (-40%)
Liabilities: $4 M (49%)
Common Stock, Value, Issued: $56 Th (0%)
Common Stock, Shares, Issued: $57 M (0%)
Retained Earnings (Accumulated Deficit): $226 M (4%)
Stockholders' Equity (Parent): $35 M (0%)
Liabilities and Equity: $41 M (-14%)
Research and Development: $5 M (-31%)
General and Administrative Expenses: $1 M (-50%)
Operating Income/Loss: $6 M (-37%)
Other Income, net: $12 Th (-25%)